Modelling the value of innovative treatments for Alzheimer's disease in the United States.
Modelling the value of innovative treatments for Alzheimer's disease in the United States.
复制标题
模拟美国阿尔茨海默病创新疗法的价值。
DOI：
10.1080/13696998.2021.1927747
复制
发表时间：
2021
影响因子：
2.4
通讯作者：
Goldman,Dana
中科院分区：
文献类型：
--
作者：
Makin,Charles;Neumann,Peter;Peschin,Sue;Goldman,Dana
阿尔茨海默病（AD）是痴呆的主要原因，也是全球主要的死亡原因。由于没有治愈或治疗方法来减缓疾病进展，AD相关的医疗保健费用是巨大的，并随着疾病的严重程度的进展而增加。鉴于这种疾病的复杂性，包括在临床表现之前几十年发生的初始病理生理损伤，寻找新的有效治疗AD依赖于高度创新的研究和开发。然而，如此大规模和持续的投资带来了传统价值评估模型是否适合这一目的的问题。在这篇文章中，我们研究了吸收不同利益相关者的观点的重要性和挑战，包括患者，护理人员，卫生系统，支付者和整个社会，成为一个全面的价值评估模型，可能非常适合AD的突破性治疗。
Alzheimer’s disease (AD) is the predominant cause of dementia and a leading cause of death globally. With no cure or treatment to slow disease progression, AD-related healthcare costs are substantial and increase as the severity of the disease progresses. Given the complexity of this disease, including initial pathophysiological damage occurring decades before clinical manifestation, finding new impactful treatments for AD relies on highly innovative research and development. However, such sizable and sustained investments bring into question whether conventional value assessment models are fit for this purpose. In this article, we examine the importance and challenges of assimilating the perspectives of varied stakeholders, including patients, caregivers, health systems, payers, and society at large, into a comprehensive value assessment model that may be well suited for a breakthrough treatment for AD.